Summary:
- Valneva, a specialty vaccine company, has reported preliminary unaudited revenue for 2024 and provided an outlook for 2025.
- The company's 2024 revenue is expected to be between €1.1 billion and €1.3 billion, driven by the continued strong performance of its COVID-19 vaccine and other vaccine products.
- For 2025, Valneva expects revenue to be in the range of €1.2 billion to €1.4 billion, reflecting the company's confidence in the growth potential of its vaccine portfolio.